Patheon — Q1 2006 Earnings Presentation
10 slides from Patheon's earnings presentation, Mar 3, 2006
Slide 1: Q1 2006 Financial Results Conference Call
Q1 2006 FINANCIAL RESULTS CONFERENCE CALL March 3, 2006 10:00 a.m. (EST) Forward-looking Information This presentation contains forward-looking statements, which reflect management’s expectations regarding the Company’s future growth, results of operations, performance (both operat ional and financi
Slide 2: Presenting on Behalf of Patheon / Agenda
Presenting on Behalf of Patheon Robert Tedford Chief Executive Officer Nick DiPietro President and Chief Operating Officer Rodger Roden Chief Financial Officer and Senior Vice-President, Finance Agenda Opening comments/strategic highlights (R. Tedford) Q1 2006 financial results (R. Roden) Revi
Slide 3: Overview of the Quarter
Overview of the Quarter A challenging quarter Greater-than-expected impact of Omnicef® Deferred orders to later quarters at Monza Production issues at Swindon, Whitby Lower OTC volumes Canadian PDS growth constrained primarily by capacity issues at TRO Revising outlook for the full year I
Slide 4: Q1 2006 Financial Highlights
Q1 2006 Financial Highlights Revenues up 3% to $157.9M Rx, PDS up 5%, OTC down 10% Europe up 12% (23% on CER basis), NA down 1% EBITDA margin of 8.9% vs. 14.1% EBITDA of $14.0M vs. $21.6M Excluding impact of one-time costs, loss of 5.8¢ per share Net loss of $11.5M, or 12.4¢ per share, vs
Slide 5: Depreciation, Amortization, Interest; Earnings (Loss)
Depreciation, Amortization, Interest Q1 2006 Depreciation and amortization expense increase of $2.0M Amortization of intangibles increase of $2.1M Interest expense increase of $2.8M Increases reflects inclusion of a full quarter of expenses relating to the MOVA acquisition vs. five weeks in
Slide 6: Cash Provided by Operating Activities
Cash Provided by Operating Activities Q1 2006 Cash provided from operations of $7.8M vs. $20.5M a year ago Additions to capital assets of $13.9M vs. $13.5M a year ago Establishment of lyo ceph capability at Swindon Establishment of high-potency at Bourgoin-Jallieu Consolidated interest-beari
Slide 7: Q1 Revenue Growth
Q1 Revenue Growth Europe European revenues grew $5.2M or 12% ($9.8M or 23% on CER basis) Rx revenues up 13% Improved volumes at Swindon Continuing strong demand for lyo services in Italy Revenues from carve-outs in Italy, France PDS revenues up 14% Solid base of business at Swindon Europea
Slide 8: Outlook: Continued growth in PDS Projects
Continued growth in PDS Projects Preclinical Preclinical Phase I Phase Phase IIII Phase Phase III III NDA NDA Total Q1-06 23 37 58 28 6 152 Y/E-05 20 38 53 30 6 147 Y/E-01 5 8 11 11 5 40 15 product launches since 2001, Including one in Q1 2006 OUTLOOK Q1 2006 Webcast Presentation 8
Slide 9: Outlook
Outlook We continue to expect 2006 to be challenging, with stronger performance in second half Expecting full-year EBITDA and net earnings to be lower than fiscal 2005 operating challenges in Q1 greater-than-anticipated declines in base business Improved results in Q2, further improvement in se
Slide 10: A New Era
A NEW ERA Q1 2006 Webcast Presentation 10